methylphenobarbital 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
hypnotics, barbituric acid derivatives 1696 115-38-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mephobarbital
  • mephobarbitone
  • methylphenobarbital
  • methylphenobarbitone
  • metylfenemal
A barbiturate that is metabolized to PHENOBARBITAL. It has been used for similar purposes, especially in EPILEPSY, but there is no evidence mephobarbital offers any advantage over PHENOBARBITAL.
  • Molecular weight: 246.27
  • Formula: C13H14N2O3
  • CLOGP: 1.85
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 66.48
  • ALOGS: -2.54
  • ROTB: 2

Drug dosage:

DoseUnitRoute
0.50 g O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 40.61 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 73 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1935 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N03AA01 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Barbiturates and derivatives
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
MeSH PA D006993 Hypnotics and Sedatives
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:35623 anticonvulsants

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Anxiety indication 48694002
Apprehension indication 49971008
Tension indication 53489000
Epilepsy indication 84757009 DOID:1826
Tonic-clonic epilepsy indication 352818000 DOID:7725
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Hepatic encephalopathy contraindication 13920009 DOID:13413
Depressive disorder contraindication 35489007
Hyperactive behavior contraindication 44548000
Hepatic failure contraindication 59927004
Substance abuse contraindication 66214007
Hepatic coma contraindication 72836002 DOID:12550
Sleep apnea contraindication 73430006 DOID:0050847
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Sleep automatism contraindication 247962006
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Respiratory insufficiency contraindication 409623005
Porphyria contraindication 418470004
Acute exacerbation of asthma contraindication 708038006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.68 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
GABA-A receptor alpha-1/beta-3/gamma-2 Ion channel WOMBAT-PK

External reference:

IDSource
4018245 VUID
N0000146576 NUI
D00700 KEGG_DRUG
4018245 VANDF
C0025382 UMLSCUI
CHEBI:6758 CHEBI
CHEMBL399103 ChEMBL_ID
CHEMBL253331 ChEMBL_ID
CHEMBL45029 ChEMBL_ID
DB00849 DRUGBANK_ID
8271 PUBCHEM_CID
6758 RXNORM
11888 MMSL
5049 MMSL
d00919 MMSL
001417 NDDF
387252006 SNOMEDCT_US
46709004 SNOMEDCT_US
D008618 MESH_DESCRIPTOR_UI
2901 INN_ID
5NC67NU76B UNII

Pharmaceutical products:

None